Mammoth Biosciences
Mammoth Biosciences raises $195M Series D at $1B valuation
Mammoth Biosciences: Series D Funding Round
Mammoth Biosciences has successfully raised $195M in Series D funding, reaching a valuation of $1B.
Company Overview
CRISPR-based diagnostics and therapeutics
Funding Details
The Series D round was led by Decheng Capital, with participation from Greenoaks Capital, Mayfield, NFX, 8VC, Plum Alley Ventures.
Company Information
- Headquarters: 3478 Buskirk Avenue, Pleasant Hill, CA 94523
- Founded: 2017
- Employees: 150+
- Category: Biotech
Investment
Mammoth Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Decheng Capital: Verified investor in Series D
- Greenoaks Capital: Verified investor in Series D
- Mayfield: Verified investor in Series D
- NFX: Verified investor in Series D
- 8VC: Verified investor in Series D
- Plum Alley Ventures: Verified investor in Series D
Company Info
Investors (6)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free